Arvinas And Pfizer Announced Topline Results From The Phase 3 VERITAC-2 Trial Of Vepdegestrant Monotherapy Versus Fulvestrant In Adults With Advanced Or Metastatic Breast Cancer, The Trial Met Its Primary Endpoint Demonstrating A Statistically...
Gilead Sciences Analyst Ratings
'Novartis Sees Radioactive Cancer Drugs Becoming $10B Business: CEO' - Nikkei Asia
GSK Shares Rise for Seven Consecutive Sessions
Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
Amgen Set for Seven Straight Sessions of Gains